Key result
Wearable therapeutic ventricular assist devices for less than 6 months of use are recommended for development to be combined with drugs, apheresis, and cellular implants.
Answers are grounded in this paper and cite their sources.
The authors propose shifting the focus of artificial heart development towards short-term wearable therapeutic VADs rather than permanent implantable devices.
As a therapeutic VAD to be combined with drugs, apheresis, and cellular implants, it is advisable to develop a wearable VAD for less than 6 months of application. Such an example was shown by describing the therapeutic BCM Gyro centrifugal VAD.
No takes yet. Share an insight, caveat, or question.
Nosé et al. (2010) studied this question. Wearable therapeutic ventricular assist devices for less than 6 months of use are recommended for development to be combined with drugs, apheresis, and cellular implants.
Synapse has enriched 10 related papers. Consider them for comparative context: